Abstract
The purpose of research — to develop a pharmacogenetic test to predict the speed and features of a metabolism of anticonvulsants, antipsychotics, antidepressants, depending on genetically determined activity of enzyme systems and proteins-transporters of drugs. Materials and Methods. During 4 years in the study included 260 patients with epilepsy and schizophrenia, located on the hospital treatment in the Centre of Mental Health (Minsk). Patients characterized by the presence of side effects and drug-resistance. Results. As a result, taking into account the genetic information in 79% of patients with epilepsy and in 73% of patients with schizophrenia, there was a significant clinical effect. Conclusion. The results demonstrated the great significance of pharmacokinetic and pharmacodynamic characteristics of the particular patient in the development of pharmacoresistance, regardless of nosology. The genetics of drug metabolism can improve the treatment and reduce the time to achieve clinical benefit from the treatment.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
